![]() |
市場調查報告書
商品編碼
1953962
微載體市場-全球產業規模、佔有率、趨勢、機會及預測(依產品、應用、最終用戶、地區及競爭格局分類,2021-2031年)Microcarriers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By End-User, By Region & Competition, 2021-2031F |
||||||
全球微載體市場預計將從 2025 年的 29.1 億美元成長到 2031 年的 41.1 億美元,複合年成長率為 5.92%。
隨著這些特化的支撐基質使依賴貼壁生長的細胞能夠在懸浮生物反應器中生長,全球微載體市場持續擴張,從而推動了從實驗室規模的平板培養向工業生物加工的轉變。這一成長主要源於疫苗和再生醫學領域對可擴展生產解決方案的迫切需求,在這些領域,大規模生產是商業性成功的關鍵。根據國際細胞與基因治療學會(ISCT)的數據,到2024年,全球在研細胞和基因療法將達到3063種,凸顯了維持這一強勁臨床發展勢頭對高密度培養系統的關鍵需求。
| 市場概覽 | |
|---|---|
| 預測期 | 2027-2031 |
| 市場規模:2025年 | 29.1億美元 |
| 市場規模:2031年 | 41.1億美元 |
| 複合年成長率:2026-2031年 | 5.92% |
| 成長最快的細分市場 | 消耗品 |
| 最大的市場 | 北美洲 |
然而,下游加工和細胞回收的技術複雜性為市場推廣帶來了顯著障礙。大型生物反應器中高動態剪切應力會對細胞活力構成威脅,而將細胞從載體上分離且不損傷細胞所需的複雜通訊協定往往會導致產量降低。這些挑戰使得標準化、一致且經濟高效的生產流程變得困難,從而極大地阻礙因素了其在市場上的廣泛應用。
細胞和基因治療臨床管線的快速擴張是全球微載體市場的主要驅動力,由此產生了對可擴展培養系統的迫切需求,以促進從研究到商業化的轉化。隨著罕見疾病和腫瘤治療方法的進展,傳統2D平面培養的局限性日益凸顯,因此需要利用微載體實現高密度懸浮培養,以確保批次間的一致性並達到商業化水平的病毒載體滴度。根據再生醫學聯盟於2024年10月發布的《產業趨勢》報告,預計該領域在2024年上半年將吸引109億美元的投資,而對後期研發的大力資助將直接推動先進生物製程耗材的採購。
此外,對可擴展的細胞疫苗生產的需求不斷成長,也促使市場更加依賴微載體技術進行高通量病毒生產。為了維持全球疫苗接種覆蓋率,製造商正在加速將一次性生物反應器與微載體結合,以在不擴大設施面積下,最大限度地增加依賴附著的病毒宿主(例如Vero細胞)的表面積。世界衛生組織(WHO)於2024年6月發布的《2023年全球疫苗市場報告》指出,2022年全球疫苗市場(不包括新冠肺炎疫苗)的產量將達到約50億劑,這表明市場對高效的大規模生產平台的需求持續存在。這種不斷成長的需求也在推動產業結構的變革。 CPHI於2024年10月發布的年度報告預測,到2028年,契約製造組織(CMO)將控制全球40%的生物製藥產能。這表明,微載體的工業化應用正轉向外包。
與下游製程最佳化和細胞回收相關的技術難題是限制全球微載體市場成長的關鍵因素。這些挑戰直接增加了銷貨成本,限制了治療方法的商業性動態,阻礙了市場擴張。大型生物反應器內產生的流體動力剪切應力通常會損傷依賴細胞黏附的細胞,而將這些細胞從微載體上分離所需的複雜通訊協定往往會導致顯著的產量損失。因此,製造商面臨著高失敗率和批次品質差異,阻礙了他們從臨床試驗階段過渡到盈利的大規模生產。
收穫階段的產量損失會削弱整個生物製程的經濟可行性,迫使企業維持高價位,從而限制患者獲得治療的機會和市場滲透率。這種瓶頸導致只有極少數治療方法能夠克服生產障礙並取得商業性成功。根據再生醫學聯盟預測,到2025年,全球75%的細胞和基因療法收入將來自不到10種上市產品。如此高的營收集中度凸顯了龐大的研發管線難以克服生產和規模化生產的障礙,從而抑制了整個微載體市場的成長潛力。
生物可分解微載體的日益普及正在革新收穫階段,解決了細胞脫落和產量損失等技術瓶頸。透過使用可溶解或分解的基質,製造商可以消除細胞分離通常所需的機械剪切力,從而簡化下游加工過程並保持細胞活力。隨著主要供應商開發適用於工業工作流程的專用解決方案,這項創新正獲得商業性認可。例如,Cultivated X 在 2025 年 10 月報道稱,康寧公司已公佈一項可食用微載體的專利,該微載體旨在保留在最終產品中,從而無需高成本的分離步驟,並有助於提高生產效率。
同時,為最大限度降低病毒污染風險並滿足嚴格的監管安全標準,市場正經歷著向無動物成分和無異種成分材料配方的重大轉變。這一轉變尤其受到新興的培養肉產業的推動,該產業需要食品級、無動物成分的支架來確保消費者安全和產品一致性。這一細分市場的蓬勃發展正在推動尖端材料的採購。根據良好食品研究所 (Good Food Institute) 2025 年 4 月發布的報告《行業趨勢:培養肉、海鮮和配料》,預計該行業的公司將在 2024 年籌集 1.39 億美元資金,這凸顯了對安全、無動物成分生物加工技術開發和應用的強勁投資。
The Global Microcarriers Market will grow from USD 2.91 Billion in 2025 to USD 4.11 Billion by 2031 at a 5.92% CAGR. The Global Microcarriers Market is expanding as these specialized support matrices enable anchorage-dependent cells to thrive in suspension bioreactors, facilitating the shift from laboratory-scale planar cultures to industrial bioprocessing. This growth is primarily driven by the urgent need for scalable manufacturing solutions in the vaccine and regenerative medicine sectors, where mass production is essential for commercial success. Data from the International Society for Cell & Gene Therapy indicates that in 2024, the global pipeline contained 3,063 cell and gene therapies, highlighting the critical demand for high-density culture systems to sustain this intense clinical momentum.
| Market Overview | |
|---|---|
| Forecast Period | 2027-2031 |
| Market Size 2025 | USD 2.91 Billion |
| Market Size 2031 | USD 4.11 Billion |
| CAGR 2026-2031 | 5.92% |
| Fastest Growing Segment | Consumables |
| Largest Market | North America |
However, market adoption faces significant hurdles due to the technical complexities involved in downstream processing and cell harvesting. High hydrodynamic shear stress within large bioreactors poses a risk to cell viability, while the intricate protocols required to detach cells from carriers without damage often lead to yield reductions. These challenges complicate the standardization of consistent, cost-effective manufacturing workflows, thereby acting as a substantial restraint on broader market integration.
Market Driver
The rapid expansion of the clinical pipeline for cell and gene therapies serves as the primary catalyst for the Global Microcarriers Market, creating an urgent demand for scalable culture systems that facilitate the transition from research to commercialization. As treatments for rare diseases and oncology advance, the limitations of traditional 2D planar cultures become unsustainable, necessitating the use of high-density suspension cultures enabled by microcarriers to ensure lot-to-lot consistency and achieve commercial viral vector titers. The Alliance for Regenerative Medicine's October 2024 'State of the Industry' update noted that the sector attracted $10.9 billion in investment during the first half of 2024, signaling strong financial backing for late-stage development that directly fuels the procurement of advanced bioprocessing supplies.
Additionally, the escalating demand for scalable cell-based vaccine production reinforces the market's reliance on microcarrier technology for high-throughput viral manufacturing. To maintain global immunization coverage, manufacturers are increasingly integrating single-use bioreactors with microcarriers to maximize the surface area for anchorage-dependent viral hosts, such as Vero cells, without increasing facility footprints. The World Health Organization's '2023 Global Vaccine Market Report' from June 2024 highlighted that the global vaccine market volume, excluding COVID-19 products, was approximately 5 billion doses in 2022, underscoring the sustained need for efficient large-scale platforms. This pressure is also driving industry structural changes; the October 2024 CPHI Annual Report projects that contract manufacturing organizations will control 40% of global biologics capacity by 2028, indicating a shift toward outsourced, industrial-scale microcarrier usage.
Market Challenge
The technical difficulty associated with optimizing downstream processing and cell harvesting represents a significant factor impeding the growth of the Global Microcarriers Market. This challenge hampers market expansion by directly inflating the Cost of Goods Sold (COGS) and limiting the commercial scalability of therapies. Hydrodynamic shear stress generated in large bioreactors often damages anchorage-dependent cells, while the complex protocols required to detach these cells from microcarriers frequently lead to substantial yield losses. Consequently, manufacturers face high failure rates and inconsistent batch quality, which prevents the successful transition from clinical trials to profitable, mass-scale production.
When yield losses occur during the harvesting phase, the economic viability of the entire bioprocess is compromised, forcing companies to maintain high price points that restrict patient access and market adoption. This bottleneck creates an environment where only a small fraction of therapies can successfully navigate manufacturing hurdles to achieve commercial success. According to the Alliance for Regenerative Medicine, in 2025, 75% of global revenue within the cell and gene therapy sector was generated by fewer than ten commercial products. This high concentration of revenue highlights the inability of the broader pipeline to overcome manufacturing and scaling barriers, thereby stalling the overall growth potential of the microcarriers market.
Market Trends
The increasing adoption of biodegradable microcarriers is revolutionizing the harvesting phase by addressing technical bottlenecks related to cell detachment and yield loss. By employing matrices that dissolve or degrade, manufacturers can eliminate the mechanical shear forces typically required to separate cells, thereby streamlining downstream processing and preserving cell viability. This innovation is gaining commercial traction as major suppliers develop specialized solutions for industrial workflows; for instance, Cultivated X reported in October 2025 that Corning Inc. published a patent for edible microcarriers designed to remain in the final product, removing the need for costly separation steps and facilitating efficient production cycles.
Simultaneously, a significant shift toward animal-component-free and xenogeneic-free material formulations is reshaping the market, driven by the imperative to minimize viral contamination risks and meet stringent regulatory safety standards. This transition is particularly accelerated by the emerging cultivated meat sector, which requires food-grade, non-animal scaffolds to ensure consumer safety and product consistency. The financial vitality of this niche is fueling the procurement of these advanced materials; the Good Food Institute's April 2025 report, 'State of the Industry: Cultivated meat, seafood, and ingredients,' noted that companies in this sector raised $139 million in 2024, highlighting the robust investment supporting the development and adoption of safe, animal-free bioprocessing technologies.
Report Scope
In this report, the Global Microcarriers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Microcarriers Market.
Global Microcarriers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: